Adult hippocampal neurogenesis is a critical form of cellular plasticity that is greatly influenced by neural activity. Among the neurotransmitters that are widely implicated in regulating this process are serotonin and norepinephrine, levels of which are modulated by stress, depression and clinical antidepressants. However, studies to date have failed to address a direct role for either neurotransmitter in regulating hippocampal precursor activity. Here we show that norepinephrine but not serotonin directly activates self-renewing and multipotent neural precursors, including stem cells, from the hippocampus of adult mice. Mechanistically, we provide evidence that ␤ 3 -adrenergic receptors, which are preferentially expressed on a Hes5-expressing precursor population in the subgranular zone (SGZ), mediate this norepinephrine-dependent activation. Moreover, intrahippocampal injection of a selective ␤ 3 -adrenergic receptor agonist in vivo increases the number of proliferating cells in the SGZ. Similarly, systemic injection of the ␤-adrenergic receptor agonist isoproterenol not only results in enhancement of proliferation in the SGZ but also leads to an increase in the percentage of nestin/glial fibrillary acidic protein double-positive neural precursors in vivo. Finally, using a novel ex vivo "slice-sphere" assay that maintains an intact neurogenic niche, we demonstrate that antidepressants that selectively block the reuptake of norepinephrine, but not serotonin, robustly increase hippocampal precursor activity via ␤-adrenergic receptors. These findings suggest that the activation of neurogenic precursors and stem cells via ␤ 3 -adrenergic receptors could be a potent mechanism to increase neuronal production, providing a putative target for the development of novel antidepressants.
Introduction
The adult mammalian hippocampus harbors neural precursors that reside and proliferate in the milieu of the neurogenic niche (Ming and Song, 2005) to generate neurons that functionally integrate into the hippocampal neurocircuitry, thereby influencing functions such as learning and memory (Lledo et al., 2006) . Accumulating evidence has suggested an important role for synaptic activity in regulating this process (Ming and Song, 2005; Zhao et al., 2008) . Neural excitation has been shown to activate a latent stem cell pool (Walker et al., 2008) , to promote the commitment of precursors to a neurogenic fate (Deisseroth et al., 2004) , as well as to enhance the survival and integration of newly born neurons in the adult hippocampus (Ge et al., 2006; Tashiro et al., 2006) . Among the factors that are released following synaptic activity are the neurotransmitters, trophic roles for which are increasingly being appreciated in the regulation of neurogenesis (Vaidya et al., 2007; Hagg, 2009 ). Recent studies have also shown that glutamate and GABA receptors are present on a subset of adult hippocampal precursors and regulate their proliferation (Ge et al., 2007; Nácher et al., 2007) .
Within the monoaminergic neurotransmitter family, a large number of in vivo studies have focused on the roles of serotonin and norepinephrine (NE), revealing a strong correlation between their levels and the extent of hippocampal neurogenesis Daszuta, 1999, 2000; Kulkarni et al., 2002) Furthermore, impaired neurogenesis has been demonstrated in animal models of stress and depression (Malberg and Duman, 2003; Vollmayr et al., 2007) , where a significant reduction in the levels of serotonin and norepinephrine is also commonly observed (Charney, 1998; Vaidya et al., 2007) . In agreement with these lines of evidence, pharmacological agents, such as antidepressants that act by elevating levels of serotonin and norepinephrine, have been shown to enhance hippocampal neurogenesis (Malberg et al., 2000) . To date, a proliferative role has been proposed for norepinephrine (Kulkarni et al., 2002) , whereas controversy still exists regarding the role of serotonin in regulating the proliferation of hippocampal precursors (Santarelli et al., 2003; Encinas et al., 2006; Holick et al., 2008; Huang et al., 2008) . However, one of the limitations of the current in vivo approaches is the inability to dissect out direct versus non-cell-autonomous effects of these neurotransmitters on the precursor population. Whether serotonin or norepinephrine has a direct effect on adult hippocampal precursors, and the cellular and molecular identity of such a precursor population, therefore remains unknown.
In the present study, we investigated the effects of serotonin and norepinephrine on adult hippocampal precursors in vitro using the neurosphere assay. We report that norepinephrine but not serotonin directly activates a self-renewing and multipotent population of stem and precursor cells. We then demonstrate that this effect is mediated by ␤ 3 -adrenergic receptors both in vitro and in vivo. Finally, we examine the effects of two major classes of widely prescribed antidepressants in a novel slicesphere assay and show that norepinephrine-selective reuptake inhibitors (NRIs) but not serotonin-selective reuptake inhibitors (SSRIs) significantly enhance hippocampal neural precursor activity via ␤-adrenergic receptors.
Materials and Methods
Animals. Adult male (8 -12 weeks old) mice were used for the majority of the experiments in this study except for the slice-sphere assay where postnatal day 7 Wistar pups were used. Mice expressing enhanced green fluorescent protein (GFP) under the control of the Hes5 promoter were generated by the Gene Expression and Nervous System Atlas Consortium (Gensat) and were obtained from the Mutant Mouse Regional Resource Center (University of Missouri). Adult male Nestin-GFP mice, maintained on a C57BL/6 background were generated as previously described (Yu et al., 2005) . Animals were treated in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and ethics approval was obtained for all experiments from the appropriate institutional Animal Ethics Committee.
Adult hippocampal neurosphere culture. Adult male C57BL/6 mice were killed by cervical dislocation and their brains removed. Brains were bisected along the midline in the sagittal plane. The hippocampi were isolated from the overlying cortex and minced using a scalpel blade. Minced tissue was digested in 0.1% papain (Invitrogen) for 20 min at 37°C, after which an excess of NeuroCult NSC basal medium (StemCell Technologies) was added to halt the digestion. Tissue was then centrifuged at 100 relative centrifugal force for 5 min, the resulting pellet was resuspended in 1 ml of complete neurosphere medium, and a single-cell suspension was achieved by gentle trituration. The cells were filtered through a 40 m cell sieve (BD Biosciences) and resuspended in NeuroCult NSC basal medium containing NeuroCult proliferation supplements (StemCell Technologies), 2% bovine serum albumin (Invitrogen) and 2 g/ml heparin (Sigma-Aldrich). The growth factors added were 20 ng/ml epidermal growth factor (EGF; receptor grade, BD Biosciences) and 10 ng/ml basic fibroblast growth factor (bFGF; recombinant bovine, Roche). The cells were then plated in a 96-well plate and cultured in complete neurosphere medium containing EGF and bFGF, in the presence or absence of 5-hydroxytryptamine hydrochloride (serotonin; 100 nM, 1 M, 10 M), L-(Ϫ)-noradrenaline (ϩ)-bitartrate salt monohydrate (norepinephrine; 100 nM, 1 M, 10 M) or KCl (15 mM). The concentrations of norepinephrine and serotonin used were based on previous reports (Segal, 1980; Lacaille and Harley, 1985) . The adrenergic receptor antagonists used were prazosin (100 nM), yohimbine
propyl]phenoxy]acetic acid sodium hydrate] was used as a selective ␤ 3 -adrenergic receptor agonist (1 and 10 M). All the compounds were purchased from Sigma-Aldrich. The number of primary neurospheres was counted on days 10 -13 and expressed as a percentage relative to the control. Passaging of single primary neurospheres was done essentially as described by Walker et al. (2008) .
Immunocytochemistry. Control or norepinephrine-stimulated neurospheres were plated onto poly-ornithine-coated coverslips or poly-Dlysine-coated BioCoat eight-well culture slides (BD Biosciences) in serum-free basal medium without any mitogens. The neurospheres were allowed to flatten and adhere for 4 -6 d in a humidified, 5% CO 2 incubator. They were then fixed with 4% paraformaldehyde in 0.1 M PBS at 4°C for 40 min, and immunocytochemistry was performed as described previously (Bull and Bartlett, 2005 ) using antibodies to the neuronal marker ␤III tubulin (1:2000; Promega), the astrocytic marker glial fibrillary acidic protein (GFAP; 1:500; Dako Cytomation) and the oligodendrocyte marker myelin basic protein (MBP; 1:500; Millipore). 4Ј,6Ј-Diamidino-2-phenylindole (DAPI; 1:5000; Sigma-Aldrich) was used as a nuclear stain. Slides were mounted using fluoromount (Dako Cytomation) and viewed on a Zeiss-Axio Imager microscope. Images were captured using a digital camera linked to a computer using Zeiss software.
Surgery and drug treatments. Adult male C57BL/6 mice were anesthetized with a mixture of ketamine (130 mg/kg; Apex Laboratories) and the muscle relaxant xylazine (6 mg/kg; Bayer). The mouse was then placed in a stereotaxic frame (David Kopf Instruments) , with the incisor bar maintained at ϳ3.3 mm below horizontal to achieve a flat skull position. Bilateral injections were performed using a glass needle (exterior diameter 20 m) fashioned from a borosilicate glass capillary (World Precision Instruments) and attached to a 5 l Hamilton syringe. The needle was lowered into the hilus region of the hippocampus (anteroposterior, Ϫ1.3 mm; mediolateral, Ϯ0.9 mm; dorsoventrial, Ϫ2.0 mm from bregma). The hilus from one hemisphere received an injection (0.5 l) of the selective ␤ 3 -adrenergic receptor agonist BRL37344 (10 M); with the contralateral hemisphere receiving a control injection of 0.9% saline. Infusions were conducted over 5 min and the needle was left in place for a further 10 min to allow for diffusion. At 1 and 24 h following surgery all mice received injections (75 mg/kg, i.p.) of bromodeoxyuridine (BrdU). Three days after the initial BRL37344 infusion, the animals were deeply anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and transcardially perfused with 4% paraformaldehyde in 0.1 M PBS. Brains were blocked using a matrix (Stoelting) aligned to the mouse brain atlas (Paxinos and Franklin, 2001) , and 40 m coronal sections were cut through the hippocampus using a sliding microtome (Leica, SM2000r) in four serially adjacent sets and stored in 0.1% sodium azide in 0.1 M PBS. One set of sections (160 m apart) was processed for BrdU immunohistochemistry, while the second set of sections was mounted on a chrome alum/ gelatinized glass slide and stained with cresyl violet. Injection placements were verified under the microscope using the boundaries defined by Paxinos and Franklin (2001) .
To study the influence of ␤-adrenergic receptor stimulation on adult hippocampal progenitors, the ␤-adrenergic receptor agonist, isoproterenol (2 mg/kg, Sigma) was used. The choice of drug dose was based on previous studies (Ozawa et al., 1969; Yuan et al., 2000) , with 0.9% saline being used as the vehicle. Nestin-GFP mice received the drug via intraperitoneal injection, once daily for seven d. All mice received BrdU (100 mg/kg, i.p.) 2 h following the last injection and were killed 24 h later by transcardial perfusion using 4% paraformaldehyde.
Immunohistochemistry. Hes5-GFP mice were perfused transcardially using ice-cold 4% paraformaldehyde. Brains were removed and postfixed in 4% paraformaldehyde for 24 h, after which 50 m sections were cut using a freezing microtome. The sections were blocked in PBS containing 0.1% Triton X-100 (0.1% PBTX) and 10% normal goat serum for 1 h and then labeled with primary antibodies: anti-GFAP (1:500; Dako Cytomation), anti-doublecortin (1:500; Sapphire Bioscience) and antinestin (1:100, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA). The sections were washed three times using 0.1% PBTX and incubated for 2 h at room temperature with the secondary antibodies goat anti-mouse Alexa 568 or goat anti-rabbit Alexa 568 (1: 2000, Invitrogen), and DAPI (1:1000). BrdU immunohistochemistry was performed essentially as described previously (Kulkarni et al., 2002; Jha et al., 2006) . In brief, this involved DNA denaturation and acid hydrolysis followed by overnight incubation with mouse anti-BrdU antibody (1: 500; Roche). The secondary antibody goat anti-mouse Alexa 488 (Invitrogen) was used at 1:2000. After several washes, the sections were mounted using fluoromount (Dako Cytomation) and viewed on a ZeissAxio Imager microscope. Optical sectioning was achieved using ApoTome and images were captured using a digital camera linked to a computer using Zeiss software.
For double-label immunofluorescence for GFP and GFAP in nestin-GFP mice, 4 sections (50 m) were selected per animal. The choice of sections was such that they were from comparable bregma points across all experimental animals. The sections were incubated for 2 h with 10% horse serum (Invitrogen) before an overnight incubation at room temperature with a mixture of the primary antibodies, rabbit anti-GFP (1: 500, Invitrogen) and mouse anti-GFAP (1:1000, Sigma). Sections were then incubated with the secondary antibodies, donkey anti-rabbit IgG (1:250, Invitrogen) and donkey anti-mouse IgG (1:250, Invitrogen) for 4 h at room temperature.
Cell counting analysis. Analysis was performed on coded sections by an experimenter blind to the study code. To address the effects of ␤-adrenergic receptor stimulation on nestin/GFAP double-positive quiescent progenitors, the percentage of GFP-positive cells that colocalized with GFAP was determined by confocal microscopy using an Olympus FV1000 confocal microscope. Between 30 and 40 GFPpositive cells from four sections (250 m apart) per animal were analyzed using z-plane confocal sectioning with 1 m steps to confirm colocalization of GFP with GFAP.
Fluorescence-activated cell sorting. Brains from adult male Hes5-GFP mice were removed and hippocampi were isolated as described earlier. A live-cell suspension was prepared from the hippocampus using 0.1% papain, and the dead cells were labeled with propidium iodide (1 g/ml). GFPpositive and -negative cells were purified by fluorescence-activated cell sorting (FACS). Cells were sorted on a FACS Vantage (Becton Dickinson) with DIVA software. The GFP-negative populations was set relative to the basal fluorescence levels obtained from GFP-negative wild-type littermate controls and a conservative approach was used in selecting only high GFPexpressing cells. The cells were collected in basal medium and plated into 96-well tissue culture plates in medium containing EGF and bFGF with or without norepinephrine (10 M).
RNA extraction and cDNA synthesis. RNA was extracted from sorted Hes5-GFP-positive and -negative cells using the RNeasy Mini Kit (Qiagen). Genomic DNA was removed by DNase digestion using a DNA-free kit (Ambion). cDNA was generated using SuperScript III (Invitrogen) with oligo-dT primers.
PCR. The complete list of primer sequences used for the PCR is detailed in Table 1 . Program 1 involved initial denaturation at 95°C for 2 min, followed by 35 cycles of 95°C for 1 min and 70°C for 2 min, with a final elongation step of 72°C for 5 min as described by (Cikos et al., 2005) . Program 2 began with initial denaturation at 95°C for 2 min, followed by 32 cycles of 95°C for 30 s, 64°C for 30 s, and 72°C for 30 s, essentially as described by Evans et al. (1999) . A total of 45 cycles were used to amplify the ␤ 3 -adrenergic receptor (Adrb3).
Generation of hippocampal organotypic slices. Seven-day-old Wistar pups were killed under isoflurane-induced anesthesia, and the brains were isolated and placed in ice-cold Ringer's solution (containing, in mM: 118 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 2.5 CaCl 2 , 1.3 MgCl 2 , 25 NaHCO 3 , and 10 glucose, pH 7.2). The brain was bisected along the sagittal plane and the hippocampi were separated from the overlying cortex. The hippocampi were cut into transverse slices of 300 m thickness using a tissue slicer (Stoelting). Six to seven slices were then transferred onto a single 0.4 m Millicell-CM membrane filter (Millipore), and the filters were placed in a 6-well plate containing 1 ml of serum-free NeuroCult NSC basal medium with NeuroCult proliferation supplements (StemCell Technologies) and 2% bovine serum albumin (Invitrogen). D-Glucose (Sigma-Aldrich) was added to the medium to a final concentration of 5 mM. Four filters, each containing 6 -7 hippocampal slices, were generated from a single animal. Plates were incubated at 37°C in a humidified 5% CO 2 incubator and the slices were cultured for 6 d.
Pharmacological treatment of hippocampal slices.
To assess the influence of specific compounds on hippocampal precursor proliferation in the slice culture, compounds were added to the complete medium at the doses outlined below. Two filters were treated with the compounds for each dose per experiment. On every alternate day half the medium was removed and replaced with fresh medium containing the compounds. Slices were treated with serotonin at 10 and 100 M and norepinephrine at 1 M, 10 and 100 M. The antidepressants used were fluoxetine (1 and 10 M), citalopram (10 and 100 M), reboxetine (1 M, 10 and 100 M), atomoxetine (1 M) and maprotiline (1 M). Propranolol (10 M) was used to block ␤-adrenergic receptors in the slices.
Derivation of neurospheres from hippocampal organotypic slices. On the sixth day of culture, the hippocampal slices from each treatment group were pooled and the tissue was minced using a scalpel blade. Minced tissue was then treated with 0.1% trypsin-EDTA (Invitrogen) for 5 min at 37°C. The digestion was stopped by adding 0.014% w/v trypsin inhibitor (Sigma-Aldrich). A single-cell suspension was achieved by gentle trituration. The total number of viable cells in an aliquot was counted on a hemocytometer based on the exclusion of 0.08% trypan blue (SigmaAldrich). The cells were then cultured in complete neurosphere medium containing EGF and bFGF. A 200 l cell suspension was plated at 2500 cells/ml in a 96-well plate, resulting in a cell density of 500 cells/well. For each experiment there were 20 wells plated for each of the doses per treatment group. The plates were incubated at 37°C in a humidified 5% CO 2 incubator. The number of neurospheres obtained per well was counted after 10 d in culture and expressed as a percentage of the control.
Statistical analysis. Experiments were repeated three times unless otherwise stated and the values expressed as mean Ϯ SEM. Results were subjected to statistical analysis using the statistical software Prism (GraphPad) and analyzed using either Student's t tests or one-way ANOVA with significance determined at p Ͻ 0.05 followed by the Bonferroni post hoc test.
Results

Norepinephrine but not serotonin activates adult hippocampal stem and precursor cells and promotes neurogenesis in vitro
To examine the effect of serotonin and norepinephrine in regulating adult hippocampal precursor activity, we used the classical neurosphere assay in the presence of the conventional mitogens EGF and bFGF. The addition of serotonin at 100 nM, 1 or 10 M produced no change in neurosphere numbers ( Fig. 1 A) or size (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material) compared with the control. In contrast, a significant increase was obtained in the presence of 100 nM and 1 M norepinephrine, with a twofold increase in neurosphere numbers observed in the presence of 10 M norepinephrine ( p Ͻ 0.001, unpaired t test; Fig. 1 A) . The average size of the neurospheres derived in the presence of 1 and 10 M norepinephrine (diameter of neurosphere in m; control: 83.47 Ϯ 2.5; 100 nM NE: 78.2 Ϯ 1.5; 1 M NE: 99.33 Ϯ 2.2; 10 M NE: 113.95 Ϯ 5.4) was also significantly greater than that of the control neurospheres ( p Ͻ 0.01 in both cases; unpaired t test). Importantly, there was also the emergence of a population of very large neurospheres Ͼ200 m in diameter in the presence of 10 M norepinephrine ( Fig. 1 B, C) . Furthermore, a systematic categorization of neurospheres according to their size revealed not only a significant increase in the percentage of neurospheres measuring 100 -150 m ( p ϭ 0.012), 150 -200 m ( p ϭ 0.007) and Ͼ200 m ( p ϭ 0.004) but a concomitant reduction in the smaller neurospheres measuring Ͻ100 m ( p Ͻ 0.001) in norepinephrine (10 M) compared with the control (Fig. 1 D) . The large (Ͼ200 m in diameter) norepinephrine-derived neurospheres resembled those described previously (Walker et al., 2008) following treatment with depolarizing levels of KCl, suggesting activation of a latent stem cell pool. To ascertain whether the norepinephrine-stimulated large neurospheres indeed reflected the activation of stem cells, individual neurospheres were selected and subjected to longterm passaging to assess their self-renewal capacity. A significant proportion (71.4%, 15 of 21) of norepinephrine (10 M) stimulated large neurospheres (Ͼ200 m in diameter) could be passaged over 10 times (Fig. 2 A) compared to none of the smaller neurospheres (Ͻ200 m in diameter) from the control or norepinephrine-treated groups. Similarly, none of the neurospheres (0 of 16) stimulated with either 1 or 10 M serotonin could be passaged.
We next determined the multipotentiality of the cells present within the neurospheres generated in the presence or absence of norepinephrine (Fig. 2 B-D) . All the neurospheres examined contained GFAP-expressing astrocytes. However, only a small proportion (4 of 26 neurospheres examined) of the control neurospheres contained ␤III tubulin-positive neurons, as opposed to the majority (62 of 82 neurospheres examined) of the norepinephrine-stimulated neurospheres. One third of the norepinephrine-stimulated neurospheres contained MBPpositive oligodendrocytes (Fig. 2 E) , whereas none of the control neurospheres expressed the oligodendrocytic marker. Notably, all the norepinephrine-stimulated large neurospheres examined (n ϭ 9) contained Ͼ50 neurons. Together, these findings indicate that norepinephrine but not serotonin can activate a selfrenewing and multipotent stem cell population in the adult hippocampus.
To examine whether norepinephrine and KCl activate the same latent pool of precursors, we added both KCl (15 mM) and norepinephrine (10 M) to the cultures. This led to a 4.5-fold increase in total neurosphere numbers compared with the twofold increase observed in the presence of either norepinephrine or KCl alone ( p Ͻ 0.05, unpaired t test), suggesting that separate populations of precursors were being activated (Fig. 3A) . More importantly, there was a fivefold increase in the number of large neurospheres (Ͼ200 m in diameter) in the combined treatment group (control: 0; NE: 7.0 Ϯ 0; KCl: 6.5 Ϯ 5.5; NEϩKCl: 34.5 Ϯ 7.5; n ϭ 2 experiments), indicative of activation a much larger population of latent stem cells than previously thought (Fig. 3B ) (Walker et al., 2008) .
Norepinephrine directly stimulates proliferation of a Hes5-expressing stem and precursor cell population To determine whether norepinephrine can directly activate hippocampal precursors, it was necessary to examine the effect of norepinephrine at a clonal density. Given the very low frequency of neurosphere formation from the adult hippocampus (Bull and Bartlett, 2005) , we needed to enrich cells with neurosphereforming activity based on the use of an appropriate marker. Notch signaling has been implicated in the maintenance of neural precursors, and transgenic mice expressing GFP driven by the promoter of one of the downstream effectors of Notch, Hes5, have been used previously to isolate and enrich multipotential stem cells in the embryonic nervous system (Ohtsuka et al., 2006; Basak and Taylor, 2007) . We therefore investigated whether Hes5 could also be used as a marker to isolate and enrich for hippocampal precursors in the adult. Using Hes5-GFP transgenic mice, we examined the expression pattern in the adult hippocampus and found that GFP-expressing cells were predominantly located along the subgranular zone (SGZ) of the dentate gyrus and had a radial glia-like morphology (Fig. 4 A) . The restricted expression and the characteristic morphology of the Hes5-GFP-positive cells prompted us to further examine whether this population represented stem/precursor cells. When colabeling with known stem/precursor cell markers was analyzed in 3-5 sections per hippocampus (n ϭ 4 hippocampi) we found that 39% of the Hes5-GFP-positive cells in the SGZ (total of 927 cells examined) expressed GFAP, a marker for quiescent neural precursor or neural stem-like cells (Fig. 4 B, BЈ) , whereas 40% expressed nestin, another marker for the precursor population (total of 477 cells examined; Fig. 4C,CЈ) , suggesting that the Hes5-GFP-positive cells were part of a stem/precursor cell population. No colabeling was observed between doublecortin-and GFP-positive cells (Fig.  4 D) , indicating that Hes5-GFP does not label neuronal progenitors or newly born neurons, although several doublecortinpositive cells were found in juxtaposition with GFP-expressing cells in the SGZ (Fig. 4 DЈ) .
Next, to examine the stem cell potential of the Hes5-GFPexpressing cells, cells were sorted from the adult hippocampus based on GFP expression (Fig. 5A) . Reverse transcriptase-PCR analysis of the sorted cells showed the presence of Hes5 mRNA only in the GFP-positive population (Fig. 5B) , which represented 5.6 Ϯ 0.5% (n ϭ 5 experiments) of the total viable hippocampal cell population. Subsequently, GFP-positive and -negative cells purified using flow cytometry were cultured for neurosphere generation. On average we observed that 1 of 65.5 Ϯ 15.2 GFPpositive cells formed a neurosphere in control medium containing EGF and bFGF, with no neurospheres being obtained from the GFP-negative fraction (Fig. 5C ). More importantly, the addition of norepinephrine resulted in a twofold increase in total neurosphere numbers only in the GFP-positive population (Fig.  5C) , with the appearance of very large neurospheres (Ͼ200 m in diameter) as described above (control: 1.0 Ϯ 0.5 neurospheres vs NE: 7.3 Ϯ 0.8 neurospheres per hippocampus). Together, these findings identify Hes5 as a marker of a stem and precursor cell population in the adult hippocampus, including those cells responsive to norepinephrine, and rule out the influence of Hes5-GFP-negative cells on neurosphere formation.
Finally, to determine whether norepinephrine activated the stem cell population directly and not via release of other factors in a paracrine manner in the bulk cultures, Hes5-GFP-positive cells were plated at a clonal density in 96-well plates. Whereas 1 of 32.5 Ϯ 3.1 GFP-positive cells formed a neurosphere in the control medium, the frequency in the medium containing norepinephrine was 1 of 15.5 Ϯ 1.6, resulting in a 215.4 Ϯ 23.5% increase in neurosphere numbers, similar to that obtained in the bulk cultures. Moreover, even at clonal density a number of large neurospheres (Ͼ200 m) expressing GFP were observed in the presence of norepinephrine (data not shown). Together, these findings unequivocally demonstrate that the effect of norepinephrine is direct and specific to hippocampal neural precursors.
␤ 3 -Adrenergic receptors mediate the effects of norepinephrine Given that norepinephrine directly activated hippocampal precursors, we next sought to identify the adrenergic receptor(s) mediating this effect. Adrenergic receptors are a diverse family of receptors divided into two major subclasses, ␣ and ␤, with six members of the ␣ family and three members of the ␤ family identified to date. The hippocampal cells were treated with specific antagonists to ␣ 1 -adrenergic receptors (prazosin), ␣ 2 -adrenergic receptors (yohimbine), or ␤-adrenergic receptors (propranolol) in the presence or absence of norepinephrine (Fig. 6 A) . One-way ANOVA revealed a significant difference between groups [F (7, 20) ϭ 8.0, p ϭ 0.0001]. Both prazosin (100 nM) and yohimbine (1 M) failed to inhibit the increase in neurosphere numbers observed in the presence of norepinephrine, whereas propranolol (1 M) reduced the norepinephrine-mediated response back to control levels ( p Ͻ 0.01; Bonferroni post hoc test), suggesting that ␤-adrenergic receptors are required for norepinephrine-dependent activation of precursors. Interestingly, treatment with yohimbine in the absence of norepinephrine resulted in a significant 40% increase ( p Ͻ 0.05) in the neurosphere numbers compared with the control.
Next, to identify the subtype of ␤-adrenergic receptor involved, we tested selective antagonists to ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenergic receptors (Fig. 6 B) . One-way ANOVA revealed a significant difference between groups [F (7,16) ϭ 42.5, p Ͻ 0.0001]. CGP20712 (10 nM), a ␤ 1 -adrenergic receptor antagonist, had no effect ( p Ͼ 0.05; Bonferroni post hoc test), whereas the ␤ 2 -adrenergic receptor blocker ICI118,551 (10 nM) significantly enhanced ( p Ͻ 0.05; Bonferroni post hoc test) the norepinephrine-mediated response. Moreover, ICI118,551 in the absence of norepinephrine also increased neurosphere generation by ϳ34% ( p Ͻ 0.05) compared with the control. Only SR59230A (10 nM), a specific ␤ 3 -adrenergic receptor antagonist, completely blocked the norepinephrinemediated activation of precursors ( p Ͻ 0.001), and also significantly reduced the generation of very large neurospheres (NE: 12 Ϯ 2.08 neurospheres vs NEϩSR59230A: 3.33 Ϯ 0.88 neurospheres; p ϭ 0.018; unpaired t test). Similarly, a significant block in norepinephrine-mediated activation was observed when the purified Hes5-GFP-positive precursor population was treated with SR59230A (control: 28 Ϯ 1.0 neurospheres, NE: 45.5 Ϯ 2.5 neurospheres, NEϩSR59230A: 26.5 Ϯ 2.5 neurospheres; n ϭ 2 experiments; p ϭ 0.016, unpaired t test).
Importantly, reverse transcriptase-PCR analysis showed the presence of ␤ 3 -adrenergic receptors exclusively in the Hes5-positive population, whereas ␤ 1 -and ␤ 2 -adrenergic receptors were expressed predominantly in the Hes5-negative population (Fig. 6C) . A small amount of ␤ 2 -adrenergic receptor was also detected in the Hes5-positive cells.
Together the above findings led us to examine the effect of a selective ␤ 3 -adrenergic receptor agonist BRL37344 on neural precursor activity (Fig. 6 D) . One-way ANOVA revealed a significant difference between groups [F (3,20) ϭ 16.14, p Ͻ 0.0001]. Addition of BRL37344 (1 or 10 M) or norepinephrine led to a significant increase in neurosphere numbers compared with the control ( p Ͻ 0.001; Bonferroni post hoc test). Importantly, BRL37344 (either 1 M or10 M) treatment increased the neurosphere numbers to a similar extent to that obtained by norepinephrine treatment. Moreover, several very large neurospheres (Ͼ200 m in diameter), indicative of activation of stem cells, were observed in BRL37344-treated cultures (1 M BRL37344: 5.5 Ϯ 0.5 neurospheres and 10 M BRL37344: 7.5 Ϯ 0.5 neurospheres) compared to none in the control medium.
Stimulation of ␤ 3 -adrenergic receptors increases proliferation of hippocampal precursors in vivo
To determine whether similar enhancement of neural precursor activity occurs following stimulation of ␤ 3 -adrenergic receptors in vivo, we injected BRL37344 directly into the hippocampus (Fig. 7A-C) , given the absence of any direct evidence that BRL37344 is systemically active and crosses the blood-brain barrier. A single dose of BRL37344 (0.5 l of 10 M) was injected directly into the hilus region on the ipsilateral side, with saline (vehicle control) being injected into the contralateral side; dividing cells were then labeled with BrdU. A significant increase in the linear density of BrdU-positive cells (expressed as number of BrdU-labeled cells per mm of SGZ) was observed in the SGZ of the BRL37344-injected hippocampus compared with the contralateral saline-injected hippocampus (Fig. 7 D, E ; saline: 9.59 Ϯ 1.3 cells vs BRL37344: 13.36 Ϯ 2.0 cells; n ϭ 5; p ϭ 0.023; paired t test). This finding demonstrates that ␤ 3 -adrenergic receptor stimulation leads to proliferation of neural precursors in vivo.
We also examined the effect of systemic treatment with the ␤-adrenergic receptor agonist isoproterenol on hippocampal . ␤ 3 receptors are expressed on neural precursors, and mediate the norepinephrine-dependent activation. A, Neither the ␣ 1 -adrenergic receptor antagonist prazosin nor the ␣ 2 -adrenergic receptor blocker yohimbine had any effect on the norepinephrinestimulated increase in neurosphere numbers. Only the ␤-adrenergic receptor blocker, propranolol, completely inhibited the norepinephrine-stimulated increase in neurosphere numbers. Note that treatment with propranolol alone had no toxic effect on neurosphere production. A slight but significant increase in the number of neurospheres was also observed in the presence of yohimbine alone. B, The selective ␤ 3 blocker SR59230A completely inhibited the norepinephrine-mediated increase in neurosphere numbers. In contrast, the ␤ 1 receptor antagonist CGP20712 had no effect, whereas the ␤ 2 receptor antagonist ICI118,551 significantly increased neurosphere numbers both in the presence and absence of norepinephrine. C, Expression of ␤-adrenergic receptors in the sorted population of Hes5-GFP-positive and -negative cells by reverse transcriptase-PCR showed the presence of the ␤ 3 -adrenergic receptor exclusively in the Hes5-positive population, whereas ␤ 1 -and ␤ 2 -adrenergic receptor transcripts were expressed predominantly in the Hes5-negative population. Note that a small amount of ␤ 2 receptor mRNA was also detected in the Hes5-positive population. D, A similar increase in neurosphere numbers was observed in the presence of a selective ␤ 3 -adrenergic receptor agonist BRL37344 at 1 and 10 M, compared with treatment with norepinephrine (mean Ϯ SEM; *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001).
neural precursor activity in mice expressing GFP under the control of nestin. Mice were treated once daily for 7 d with either saline (vehicle control) or isoproterenol, and dividing cells were again labeled with BrdU. Systemic stimulation of ␤-adrenergic receptors resulted in a significant increase in the total number of proliferating cells in the SGZ (saline: 485.48 Ϯ 43.3 cells vs isoproterenol: 769.15 Ϯ 55.4 cells; n ϭ 5; p ϭ 0.0038; unpaired t test). More interestingly, it also led to a significant increase in the percentage of nestin-GFP/GFAP double-positive cells, considered to be quiescent neural precursors (for review, see Kempermann et al., 2004) in the hippocampus ( Fig. 7F ; saline: 31.00 Ϯ 2.9% vs isoproterenol: 48.84 Ϯ 3.9%; p ϭ 0.011; unpaired t test), confirming the activation of a latent neural precursor population in vivo.
Norepinephrine but not serotonin increases hippocampal precursor activity in a novel "slice-sphere" assay ex vivo The above finding that norepinephrine but not serotonin directly activates hippocampal precursors prompted us to examine whether agents such as antidepressants, which act primarily by modulating levels of these neurotransmitters, exert their neurogenic effects by directly regulating hippocampal precursor activity. Given that the primary target of actions for these drugs requires the presence of monoaminergic terminals, which can be maintained only in an intact neurogenic niche, we reasoned that the neurosphere assay, where such a niche would be lost, was less suitable for this purpose. We therefore developed a two-step slice-sphere assay (outlined in Fig. 8A-D) , essentially combining the advantages of organotypic slices, which retain the neurogenic milieu, and the neurosphere assay, which serves as a measure of quantifying precursor numbers. Hippocampal organotypic slices prepared from 7-d-old neonatal rats retained a healthy appearance after 6 d ex vivo in a serum-free culture medium. Although a significant reduction of ϳ34% in cell number (n ϭ 4 experiments, p ϭ 0.003; unpaired t test) was observed from the slices cultured for 6 d (1.43 ϫ 10 5 Ϯ 1.57 ϫ 10 4 cells/ml) compared with acute slices (day 0: 2.17 ϫ 10 5 Ϯ 1.12 ϫ 10 4 cells/ml), the frequency of neurosphere formation was remarkably similar at day 0 (28.46 Ϯ 0.6 neurospheres per 500 cells) and day 6 (25.01 Ϯ 2.1 neurospheres per 500 cells; p ϭ 0.216; unpaired t test), indicating not only that the precursors were maintained in the slices but also that they retained their normal proliferative capacity.
To determine the influence of an intact neurogenic niche and validate the usefulness of the slice-sphere assay in mediating the effects of serotonin or norepinephrine on precursor activity, hippocampal slices were treated with various concentrations of these neurotransmitters. The neurosphere frequency remained unchanged in the slices treated with serotonin (10 M: 90.07 Ϯ 5.4% and 100 M: 102.81 Ϯ 31.7%) compared with the control (Fig.  8 E) . However, a twofold increase in precursor numbers was obtained in the slice-sphere assay from slices treated with either 1 M ( p ϭ 0.026; unpaired t test) or 10 M norepinephrine ( p ϭ 0.023), consistent with our finding of an enhanced neurosphere frequency in the conventional neurosphere assay. Notably, addition of 100 M norepinephrine to the slices led to a 3.5-fold increase ( p Ͻ 0.001) in the precursor activity compared with the control. This suggests that serotonin is not able to modulate precursor activity even when the neurogenic niche is maintained. Moreover, it highlights the importance of an intact neurogenic niche in revealing a significantly larger increase in norepinephrine-dependent precursor activation than observed in the standard neurosphere assay.
Antidepressants that block reuptake of norepinephrine but not serotonin stimulate hippocampal precursor activity in the slice-sphere assay Finally, the above findings led us to examine the effect of two major classes of antidepressants on hippocampal precursor activity. Fluoxetine, a prototypical SSRI, had no effect on precursor numbers when added to the slices at a concentration of 1 M but significantly reduced the neurosphere frequency at 10 M ( Fig.  9A ; p ϭ 0.04; unpaired t test). Although fluoxetine is a potent uptake inhibitor of serotonin, it is also known to affect the activity of muscarinic, histaminergic and ␣-adrenergic receptors (Hyttel, 1994) . Hence, the effect of another potent and more specific SSRI, citalopram, was also examined. No significant change in the hippocampal precursor frequency was observed at either 10 M (113.8 Ϯ 9.9%) or 100 M (103.8 Ϯ 3.8%) citalopram compared with the control (Fig. 9A) .
In contrast, reboxetine, a widely used NRI, produced a dosedependent increase in neurosphere numbers. While the frequency of neurosphere formation remained unchanged at 1 M (104.5 Ϯ 9.6%), a significant 40% increase was observed at 10 M ( p ϭ 0.0026; unpaired t test), and more than a 2.5-fold increase (265.0 Ϯ 11.7%; p Ͻ 0.001) was observed at 100 M (Fig. 9B) . This stimulatory effect on hippocampal precursors was not exclusive to reboxetine, being observed in the presence of other members of the NRI family, namely atomoxetine and maprotiline (Fig. 9B) . Atomoxetine, at a concentration of 1 M, increased the precursor frequency to 147.0 Ϯ 15.0% (n ϭ 2 experiments), comparable to the result obtained with 10 M reboxetine treatment. Treatment of slices with 1 M maprotiline produced an even greater increase (258.5 Ϯ 25.5%) in the frequency of neurosphere formation compared with the control (n ϭ 2 experiments). Together, these results suggest that antidepressants that specifically block the reuptake of norepinephrine may exert their neurogenic effects in the hippocampus primarily through activa- tion of a precursor population. In contrast, serotonin and the antidepressants that modulate its levels appear to have no direct role in regulating hippocampal precursor activity.
Finally, to determine whether the norepinephrine-and reboxetine-mediated increase in hippocampal precursor activity involved ␤-adrenergic receptors, slices were treated with 10 M propranolol in the presence of either 10 M norepinephrine or 10 M reboxetine (Fig. 9C) . The ability of propranolol to completely inhibit the norepinephrine-mediated ( p ϭ 0.036; unpaired t test) as well as the reboxetine-mediated ( p ϭ 0.013) increase in precursor activity indicated the involvement of ␤-adrenergic receptors.
Discussion
In the present study we have demonstrated that norepinephrine, but not serotonin, activates a stem and precursor cell pool in the adult hippocampus, and have provided evidence for a direct action of norepinephrine on these precursors. Importantly, we have uncovered a novel role for ␤ 3 -adrenergic receptors in mediating the norepinephrine-dependent activation of the hippocampal precursors both in vitro and in vivo. Consistent with these results, our findings from the slice-sphere assay demonstrate that antidepressants that selectively block the reuptake of norepinephrine but not serotonin enhance hippocampal neurogenesis, primarily by targeting the activity of stem and precursor cells.
The norepinephrine-responsive precursor population appears remarkably similar to the previously identified latent population of stem and precursor cells activated by depolarizing levels of KCl (Walker et al., 2008) . The most striking common feature between norepinephrine-and KCl-mediated activation is the emergence of a small number of very large neurospheres (measuring Ͼ200 m in diameter), displaying the classic properties of stem cells, including self-renewal over multiple passages and generation of multipotential lineages. However, the additive effect in neurosphere numbers observed in the presence of both norepinephrine and KCl is indicative of activation of different pools of latent precursors. In fact, 5-fold increase in the number of large neurospheres generated in the presence of both norepinephrine and KCl, and the inability of a selective ␤ 3 -adrenergic receptor antagonist to block the KCl-dependent activation of the precursors (data not shown), suggest the existence of a much larger pool of latent precursors within the adult hippocampus than previously considered. Also noteworthy is the ability of norepinephrine to support neuronal production, with the majority of primary neurospheres grown in the presence of norepinephrine containing ␤III tubulin-positive neurons, and the larger neurospheres containing in excess of 50 neurons. This highlights the neurogenic potential of norepinephrine, which may underlie the enhanced neurogenesis observed in vivo in response to NRIs (Malberg et al., 2000) . Thus, it appears that neural activity could Figure 8 . Direct application of norepinephrine but not serotonin enhances hippocampal precursor activity in the slice-sphere assay. A, The hippocampus from a postnatal day 7 Wistar rat was dissected and cut transversely into 300 m slices. The slices were placed on a 0.4 m membrane filter that was bathed in 1 ml of complete serum-free NeuroCult medium in a 6-well 4 plate. Four filters, each containing 6 -7 slices, were generated from a single animal. B, The organotypic slices were cultured at a liquid-air interphase for a period of 6 d. Antidepressants or neurotransmitters were added to the medium on day 1 and half the medium was replaced with fresh medium every alternate day. C, On the sixth day, the hippocampal slices were enzymatically dissociated and cells were plated in a 96-well plate and cultured in the presence of EGF and bFGF to obtain neurospheres. D, The number of neurospheres generated was quantified after 10 -12 d in culture, this being representative of the number of proliferating hippocampal precursors present in the slices. E, Serotonin (5-HT) treatment had no effect on the frequency of neurosphere formation either at 10 or 100 M. However, direct application of NE to the slices resulted in an ϳ2-fold increase in the neurosphere frequency at 1 and 10 M, and a 3.5-fold increase at 100 M (mean Ϯ SEM; **p Ͻ 0.01; ***p Ͻ 0.001).
regulate hippocampal neurogenesis in multiple ways. First, neural excitation could transiently stimulate neurogenic activity through the release of paracrine factors from the neurogenic niche that could lead to a non-cell-autonomous activation of the latent pool of neural precursors (Walker et al., 2008) . Alternatively, neural activity could lead to long-term changes in gene expression of the factors associated with the neurogenic niche, such as brain-derived neurotrophic factor and FGF-1b, by epigenetic mechanisms (Ma et al., 2009) . In contrast to these mechanisms, we propose a novel mechanism whereby norepinephrine-mediated neural activity could directly and locally enhance neural precursor activity via ␤ 3 -adrenergic receptors, a possibility supported by the finding that norepinephrine-containing afferents are found in close proximity to proliferating precursors in the SGZ (Rizk et al., 2006) . Whether new neurons generated in the hippocampus in response to firing of noradrenergic neurons in the locus ceruleus or neural activity arising from other brain regions have similar or different electrophysiological properties, and the behavioral consequences of this, remains to be determined.
To date, the identity of the latent precursor population in the adult hippocampus has remained elusive. In the present study, we provide evidence that the Hes5-expressing population in the adult hippocampal SGZ contains a subset of such latent precursors. More importantly, we find that the Hes5-expressing precursor population comprises all the neurosphere-forming cells from the adult hippocampus, including the stem cell population that responds to norepinephrine. Expression of Hes5 in such a latent precursor population is not surprising, given the essential role that Notch signaling and Hes genes play in the maintenance of neural stem and precursor cells in both the developing and the adult nervous system (Kageyama et al., 2005) . Moreover, similar neurosphere frequency in bulk as well as clonal density (1 cell/ well) cultures of purified Hes5-positive precursors confirmed the direct effect of norepinephrine on adult hippocampal precursors and ruled out the involvement of paracrine factors secreted from other cells. This direct effect may underlie the twofold increase in precursor activity observed in our slice-sphere assay in the presence of either norepinephrine or antidepressants that block the reuptake of norepinephrine. Thus, we propose that Hes5 provides a valuable and robust marker for a subpopulation of stem and precursor cells in the adult hippocampus and could be used to examine the effects of other factors, including those released by neural excitation (Walker et al., 2008) .
A striking and unexpected finding of the current study was the expression of ␤ 3 -adrenergic receptors exclusively on the Hes5-positive precursor population. Until now, predominant expression of ␤3 receptors has only been reported in brown and white adipose tissue (Strosberg, 1997) , with a few reports examining their expression in various brain tissues, including the hippocampus (Summers et al., 1995; Claustre et al., 2008) . Our evidence that the nonselective ␤-adrenergic receptor blocker propranolol, as well as the selective ␤ 3 -adrenergic receptor antagonist SR59230A, completely inhibit the norepinephrine-dependent stimulation of stem and precursor cells underpins a critical and novel role for ␤ 3 -adrenergic receptors in regulating adult hippocampal precursor activity. This was further strengthened by our finding that pharmacological stimulation of ␤ 3 -adrenergic receptors both in vitro and in vivo by the selective ␤ 3 -adrenergic receptor agonist BRL37344 led to enhanced proliferation of hippocampal precursors. On the other hand, expression of ␤ 1 and ␤ 2 receptors in the Hes5-negative population was consistent with the inability of their selective antagonists to block the norepinephrine-mediated activation of precursors. In fact, a marginal but significant potentiation effect was observed in the presence of the ␤ 2 antagonist ICI118,551, suggesting an inhibitory role for ␤ 2 -adrenergic receptors in regulating precursor proliferation. Such an inhibitory role has recently been proposed for another member of the adrenergic receptor family, namely ␣ 2 -adrenergic receptors (Yanpallewar et al., 2010) , suggesting that antagonism of ␣ 2 -adrenergic receptors could also activate neural precursors and result in an increase in neurosphere numbers as observed in this study. Alternatively, ␣ 2 -adrenergic receptor antagonism may enhance survival of neural precursors, a possibility raised in a previous report (Rizk et al., 2006) that demonstrated an ␣ 2 -adrenergic receptor antagonist-mediated increase in the survival of newborn neurons. Interestingly, ␤ 3 -adrenergic receptor blockade had no effect on the baseline proliferation of precursors in the absence of norepinephrine. This raises the possibility of a specific requirement of these receptors in mediating norepinephrine-dependent regulation of hippocampal precursors, including that mediated by NRIs.
How ␤ 3 -adrenergic receptors mediate activation and proliferation of neural precursors is currently unknown. However, given that ␤ 3 -adrenergic receptors are seven transmembrane receptors coupled to heterotrimeric G-proteins that signal via multiple intracellular pathways, including activation of adenylate cyclase and cAMP-dependent phosphorylation (for review, see Ursino et al., 2009) , and that increases in the intracellular levels of cAMP regulate the proliferation of hippocampal precursors in vivo (Nakagawa et al., 2002) , it is possible that ␤ 3 -adrenergic receptordriven activation of neural precursors may also use this cAMPmediated signaling mechanism.
Also relevant to our findings are several reports describing an antidepressant-like profile for the specific and potent ␤ 3 -adrenergic receptor agonist, SR58611A (amibegron) (Simiand et al., 1992; Consoli et al., 2007; Stemmelin et al., 2008) . Interestingly, a study by Claustre et al. (2008) demonstrated that an intraperitoneal injection of SR58611A produced an up to fivefold increase in the level of hippocampal norepinephrine, consistent with enhancement of the firing rate of noradrenergic neurons present within the locus ceruleus. Given the dense innervation of noradrenergic fibers in the dentate gyrus from the locus ceruleus, together with our results demonstrating that norepinephrine can directly activate multipotent precursors, it is tempting to speculate that the antidepressant-like effect of SR58611A observed in animal models may occur via ␤ 3 -adrenergic receptor-mediated enhancement of hippocampal neurogenesis.
Finally, our data from both the standard neurosphere and slice-sphere assays, together with the lack of any evidence for the expression of serotonin receptors on neural precursors suggest that serotonin and antidepressants that modulate levels of serotonin neither directly nor via release of paracrine factors from the neurogenic niche regulate hippocampal precursor activity. It is possible that the previously reported neurogenic effects of SSRIs on precursor activity (Gould, 1999; Malberg et al., 2000) require more than just the local hippocampal niche. Given reports that the effects of SSRIs, including fluoxetine, are lost in norepinephrine-deficient mice, it has been suggested that some of these effects may involve a role for norepinephrine (Cryan et al., 2004) . Alternatively, it has been proposed that the neurogenic effects of fluoxetine require circadian rhythm-associated changes in the level of corticosterone (Huang and Herbert, 2006) . It must also be noted that the slice-sphere assay used postnatal day 7 animals, primarily due to the ease of maintaining healthy hippocampal slices ex vivo. Although many of the factors that regulate adult neurogenesis are present in the developing hippocampus, there may be a lack of specific inputs or other factors in the early postnatal brain which preclude the proliferating effects of SSRIs. Nonetheless, recent studies have shown that neither selective depletion or enhancement of serotonin (Jha et al., 2006) nor chronic treatment with fluoxetine have any effect on hippocampal precursor proliferation in vivo (Couillard-Despres et al., 2009; David et al., 2009) . Instead, improved survival and morphological changes in doublecortin-positive cells suggest a role for fluoxetine during maturation of newly born neurons (Wang et al., 2008; David et al., 2009) .
In summary, our findings suggest that stimulation of ␤ 3 -adrenergic receptors can directly activate a distinct population of precursors, including stem cells, to generate a large number of neurons in the adult hippocampus. This opens up the possibility of developing novel pharmaceutical agents to enhance neurogenesis as a means of treating a variety of psychiatric diseases, including depression.
